Oxford University announced on Thursday it will launch a medical trial alternating doses of Covid-19 vaccines created by different manufacturers, the first study of its kind, reports AFP.
The trial will show whether different Covid doses—those created by the Astrazeneca and Pfizer/BioNTech pharmaceutical companies—can be used interchangeably to allow greater flexibility in pressured vaccine delivery schedules.The British government’s Deputy Chief Medical Officer, Jonathan Van-Tam, said the trial would offer “greater insight” into the use of vaccines against Covid. “Given the inevitable challenges of immunising large numbers of the population against Covid-19 and potential global supply constraints, there are definite advantages to having data that could support a more flexible immunisation programme,” Van-Tam said.
“It is also even possible that by combining vaccines, the immune response could be enhanced giving even higher antibody levels that last longer,” he added.
The 13-month study will compare different combinations of prime and booster doses of the Astrazeneca and Pfizer vaccines at intervals of four and 12 weeks.